JP2016527286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527286A5 JP2016527286A5 JP2016532266A JP2016532266A JP2016527286A5 JP 2016527286 A5 JP2016527286 A5 JP 2016527286A5 JP 2016532266 A JP2016532266 A JP 2016532266A JP 2016532266 A JP2016532266 A JP 2016532266A JP 2016527286 A5 JP2016527286 A5 JP 2016527286A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- amino acid
- interleukin
- combined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019123809A JP7565678B2 (ja) | 2013-08-08 | 2019-07-02 | 組合せ医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003964 | 2013-08-08 | ||
| EP13003964.7 | 2013-08-08 | ||
| PCT/EP2014/002182 WO2015018529A1 (en) | 2013-08-08 | 2014-08-08 | Combined pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019123809A Division JP7565678B2 (ja) | 2013-08-08 | 2019-07-02 | 組合せ医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527286A JP2016527286A (ja) | 2016-09-08 |
| JP2016527286A5 true JP2016527286A5 (enExample) | 2017-08-24 |
| JP6794255B2 JP6794255B2 (ja) | 2020-12-02 |
Family
ID=48951300
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532266A Active JP6794255B2 (ja) | 2013-08-08 | 2014-08-08 | 組合せ医薬組成物 |
| JP2019123809A Active JP7565678B2 (ja) | 2013-08-08 | 2019-07-02 | 組合せ医薬組成物 |
| JP2022063995A Pending JP2022091985A (ja) | 2013-08-08 | 2022-04-07 | 組合せ医薬組成物 |
| JP2024092095A Withdrawn JP2024116254A (ja) | 2013-08-08 | 2024-06-06 | 組合せ医薬組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019123809A Active JP7565678B2 (ja) | 2013-08-08 | 2019-07-02 | 組合せ医薬組成物 |
| JP2022063995A Pending JP2022091985A (ja) | 2013-08-08 | 2022-04-07 | 組合せ医薬組成物 |
| JP2024092095A Withdrawn JP2024116254A (ja) | 2013-08-08 | 2024-06-06 | 組合せ医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160184399A1 (enExample) |
| EP (2) | EP3659622A1 (enExample) |
| JP (4) | JP6794255B2 (enExample) |
| KR (3) | KR102861895B1 (enExample) |
| CN (1) | CN105579062A (enExample) |
| CA (1) | CA2920539C (enExample) |
| CY (1) | CY1122465T1 (enExample) |
| DK (1) | DK3030262T3 (enExample) |
| ES (1) | ES2760249T3 (enExample) |
| HR (1) | HRP20192174T1 (enExample) |
| HU (1) | HUE046964T2 (enExample) |
| LT (1) | LT3030262T (enExample) |
| PL (1) | PL3030262T3 (enExample) |
| PT (1) | PT3030262T (enExample) |
| RS (1) | RS59756B1 (enExample) |
| SI (1) | SI3030262T1 (enExample) |
| SM (1) | SMT201900684T1 (enExample) |
| WO (1) | WO2015018529A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE037464T2 (hu) | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
| WO2014158811A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| KR102861895B1 (ko) * | 2013-08-08 | 2025-09-22 | 싸이튠 파마 | 병용 약학 조성물 |
| SI3094351T1 (sl) * | 2014-01-15 | 2022-05-31 | Kadmon Corporation, Llc | Imunomodulatorna sredstva |
| JP6857498B2 (ja) | 2014-02-27 | 2021-04-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌を処置するための併用方法 |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| CN107849112B (zh) | 2015-06-25 | 2022-04-01 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| WO2017046200A1 (en) * | 2015-09-16 | 2017-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| EP3402508A4 (en) * | 2016-01-11 | 2019-09-25 | Flagship Pioneering Innovations V, Inc. | METHOD AND COMPOSITIONS FOR MODULATING THE THYMUS FUNCTION |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| EP3468581A1 (en) | 2016-06-13 | 2019-04-17 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| EP4353750A3 (en) * | 2016-06-24 | 2024-07-24 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
| CA3032669A1 (en) * | 2016-08-01 | 2018-02-08 | William Jia | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
| KR102562519B1 (ko) * | 2016-10-14 | 2023-08-02 | 젠코어 인코포레이티드 | IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| JP2020524512A (ja) | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
| US11524033B2 (en) | 2017-09-05 | 2022-12-13 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| WO2019126240A1 (en) * | 2017-12-19 | 2019-06-27 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| EP3759129A1 (en) | 2018-02-28 | 2021-01-06 | Pfizer Inc | Il-15 variants and uses thereof |
| AU2019256539A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| KR20210003170A (ko) | 2018-04-18 | 2021-01-11 | 젠코어 인코포레이티드 | IL-15/IL-15Rα 이종이량체 Fc 융합 단백질 및 이의 용도 |
| WO2019204646A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| PE20211055A1 (es) | 2018-10-12 | 2021-06-07 | Xencor Inc | Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| MX2021014189A (es) * | 2019-05-20 | 2022-01-06 | Cytune Pharma | Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas. |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| KR20220131895A (ko) * | 2019-11-21 | 2022-09-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법 |
| KR20230096047A (ko) * | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제 |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| WO2023086772A1 (en) | 2021-11-12 | 2023-05-19 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| AU2023299307A1 (en) | 2022-06-30 | 2025-01-09 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2024186143A1 (ko) * | 2023-03-07 | 2024-09-12 | 한미약품 주식회사 | 암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 면역관문 억제제의 병용 요법 |
| EP4678180A1 (en) * | 2023-03-07 | 2026-01-14 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof |
| WO2025085672A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| HK1041274B (zh) | 1998-12-23 | 2017-12-01 | 辉瑞大药厂 | 抗ctla-4的人单克隆抗体 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| US7740845B2 (en) | 2000-10-18 | 2010-06-22 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| ATE540978T1 (de) | 2002-10-17 | 2012-01-15 | Genmab As | Humane monoklonale antikörper gegen cd20 |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP1718670B1 (en) | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| CA2601417C (en) | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| CA2589171A1 (en) | 2004-11-29 | 2006-06-01 | Pharmacia & Upjohn Company Llc | Thiazepine oxazolidinones as antibacterial agents |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| NZ563263A (en) | 2005-05-17 | 2010-04-30 | Univ Connecticut | Composition and methods for immunomodulation in an organism |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EA200970477A1 (ru) | 2006-11-15 | 2009-12-30 | Медарекс, Инк. | Человеческие моноклональные антитела к btla и способы применения |
| HUE030139T2 (en) | 2006-12-27 | 2017-04-28 | Univ Emory | Compositions and methods for the treatment of infections |
| KR20100014527A (ko) | 2007-03-22 | 2010-02-10 | 슬로안-케테링인스티튜트퍼캔서리서치 | 단일클론항체 8ｈ9의 용도 |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| EP2724727A1 (en) | 2007-06-27 | 2014-04-30 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Complexes of IL-15 and IL-15R alpha and uses thereof |
| AR069747A1 (es) | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
| EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2009135031A1 (en) | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| HUE027525T2 (en) | 2008-08-25 | 2016-11-28 | Amplimmune Inc | PD-1 Antagonist preparations and their use |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Ｐｄ−１特異抗体およびその使用 |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP3002296B1 (en) | 2009-03-17 | 2020-04-29 | Université d'Aix-Marseille | Btla antibodies and uses thereof |
| US8563694B2 (en) | 2009-07-31 | 2013-10-22 | Medarex, Inc. | Fully human antibodies to BTLA |
| BR112012022210B1 (pt) | 2010-03-04 | 2021-08-17 | Macrogenics, Inc | Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| CN105017429B (zh) * | 2010-09-21 | 2021-04-06 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| CA2888896A1 (en) * | 2012-10-24 | 2014-05-01 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| KR102861895B1 (ko) | 2013-08-08 | 2025-09-22 | 싸이튠 파마 | 병용 약학 조성물 |
-
2014
- 2014-08-08 KR KR1020247021359A patent/KR102861895B1/ko active Active
- 2014-08-08 CA CA2920539A patent/CA2920539C/en active Active
- 2014-08-08 US US14/910,491 patent/US20160184399A1/en not_active Abandoned
- 2014-08-08 WO PCT/EP2014/002182 patent/WO2015018529A1/en not_active Ceased
- 2014-08-08 CN CN201480052637.3A patent/CN105579062A/zh active Pending
- 2014-08-08 KR KR1020227036248A patent/KR20220148304A/ko not_active Ceased
- 2014-08-08 SM SM20190684T patent/SMT201900684T1/it unknown
- 2014-08-08 ES ES14761281T patent/ES2760249T3/es active Active
- 2014-08-08 EP EP19201668.1A patent/EP3659622A1/en active Pending
- 2014-08-08 HU HUE14761281A patent/HUE046964T2/hu unknown
- 2014-08-08 PL PL14761281T patent/PL3030262T3/pl unknown
- 2014-08-08 JP JP2016532266A patent/JP6794255B2/ja active Active
- 2014-08-08 RS RS20191542A patent/RS59756B1/sr unknown
- 2014-08-08 DK DK14761281T patent/DK3030262T3/da active
- 2014-08-08 HR HRP20192174TT patent/HRP20192174T1/hr unknown
- 2014-08-08 EP EP14761281.6A patent/EP3030262B1/en active Active
- 2014-08-08 LT LTEP14761281.6T patent/LT3030262T/lt unknown
- 2014-08-08 PT PT147612816T patent/PT3030262T/pt unknown
- 2014-08-08 SI SI201431420T patent/SI3030262T1/sl unknown
- 2014-08-08 KR KR1020167005437A patent/KR102457731B1/ko active Active
-
2019
- 2019-07-02 JP JP2019123809A patent/JP7565678B2/ja active Active
- 2019-11-26 CY CY20191101235T patent/CY1122465T1/el unknown
-
2022
- 2022-02-22 US US17/677,589 patent/US20220168395A1/en active Pending
- 2022-03-15 US US17/695,688 patent/US20220202904A1/en active Pending
- 2022-04-07 JP JP2022063995A patent/JP2022091985A/ja active Pending
-
2024
- 2024-06-06 JP JP2024092095A patent/JP2024116254A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527286A5 (enExample) | ||
| JP7617839B2 (ja) | 融合構築物およびその使用法 | |
| ES3006183T3 (en) | Antibody molecules that bind pd-l1 and cd137 | |
| JP7397055B2 (ja) | Ｃｄ１３７及びｏｘ４０に結合する抗体分子 | |
| HRP20192174T1 (hr) | Kombinirani farmaceutski pripravak | |
| JP7474235B2 (ja) | ＯＸ４０抗原結合部位を含むＦｃ結合断片 | |
| JP2018501197A5 (enExample) | ||
| JP2016537340A5 (enExample) | ||
| JP2016539096A5 (enExample) | ||
| JP2016532693A5 (enExample) | ||
| WO2015037000A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| HRP20212023T1 (hr) | Modulokini temeljeni na il-15 i il-15ralpha sushi domeni | |
| WO2014089169A4 (en) | Immunotherapy with binding agents | |
| RU2016122957A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
| FI3421486T3 (fi) | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi | |
| JP2017534633A5 (enExample) | ||
| JP2023165946A (ja) | Ｅｐ４阻害剤およびその使用 | |
| JP2020521478A5 (enExample) | ||
| JP2020517658A5 (enExample) | ||
| AU2021202634B2 (en) | Hla-b57 open conformers | |
| ES3040993T3 (en) | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy | |
| JP2019526528A5 (enExample) | ||
| CN113543809A (zh) | 用于治疗癌症的免疫疗法 | |
| JP2019517508A5 (enExample) | ||
| CN114599398A (zh) | 用gm-csf拮抗剂治疗癌症 |